|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
EBSCO_ocm80168779 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
070126s2006 dcua obt 100 0 eng d |
040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d YDXCP
|d OCLCQ
|d COD
|d IDEBK
|d OCLCQ
|d NTE
|d TFW
|d OCLCQ
|d OCLCA
|d OCLCF
|d OCLCQ
|d COO
|d NLGGC
|d OCLCA
|d OCLCQ
|d OCL
|d EBLCP
|d OCLCQ
|d TOA
|d AGLDB
|d ZCU
|d OCLCQ
|d MERUC
|d OCLCQ
|d MERER
|d OCLCO
|d BUF
|d OCLCO
|d GILDS
|d VNS
|d VTS
|d ICG
|d OCLCQ
|d OCLCO
|d VT2
|d OCLCQ
|d LVT
|d STF
|d WYU
|d OCLCO
|d DKC
|d OCLCQ
|d M8D
|d UKAHL
|d OCLCQ
|d OCLCA
|d OCLCQ
|d OCLCO
|d SFB
|d OCLCQ
|
016 |
7 |
|
|a 101284309
|2 DNLM
|
019 |
|
|
|a 80788951
|a 144225573
|a 748538904
|a 814470306
|a 923277128
|a 1055343085
|a 1061008044
|a 1061031298
|a 1062925274
|a 1156333220
|a 1228558181
|a 1249244865
|a 1264799208
|
020 |
|
|
|a 9780309658140
|q (electronic bk.)
|
020 |
|
|
|a 0309658144
|q (electronic bk.)
|
020 |
|
|
|a 1280704926
|
020 |
|
|
|a 9781280704925
|
020 |
|
|
|z 0309101344
|
020 |
|
|
|z 9780309101349
|
029 |
1 |
|
|a AU@
|b 000044593848
|
029 |
1 |
|
|a AU@
|b 000051474342
|
029 |
1 |
|
|a AU@
|b 000073087453
|
029 |
1 |
|
|a DEBBG
|b BV043096811
|
029 |
1 |
|
|a DEBBG
|b BV044108599
|
029 |
1 |
|
|a DEBSZ
|b 422233455
|
029 |
1 |
|
|a GBVCP
|b 802220932
|
029 |
1 |
|
|a YDXCP
|b 2514804
|
035 |
|
|
|a (OCoLC)80168779
|z (OCoLC)80788951
|z (OCoLC)144225573
|z (OCoLC)748538904
|z (OCoLC)814470306
|z (OCoLC)923277128
|z (OCoLC)1055343085
|z (OCoLC)1061008044
|z (OCoLC)1061031298
|z (OCoLC)1062925274
|z (OCoLC)1156333220
|z (OCoLC)1228558181
|z (OCoLC)1249244865
|z (OCoLC)1264799208
|
050 |
|
4 |
|a RC270.3.T84
|b P38 2006eb
|
060 |
|
4 |
|a QZ 266
|b P299d 2006
|
072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
072 |
|
7 |
|a M
|2 bicssc
|
082 |
0 |
4 |
|a 616.99/4075
|2 22
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Patlak, Margie.
|
245 |
1 |
0 |
|a Developing biomarker-based tools for cancer screening, diagnosis, and treatment :
|b the state of the science, evaluation, implementation, and economics : workshop summary /
|c Margie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum.
|
260 |
|
|
|a Washington, D.C. :
|b National Academies Press,
|c ©2006.
|
300 |
|
|
|a 1 online resource (x, 102 pages) :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references (page 92).
|
536 |
|
|
|a Study supported by contracts between the National Academy of Sciences and the Dept. of Health and Human Services
|b HHSH25056133
|b HHSN261200611002C
|b 200-2005-13434
|b HHSM-500-2005-00179P
|b HHSP23320042509XI
|b 223-01-2460
|
505 |
0 |
|
|a Cover -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Genomics, Proteomics, and Metabolomics -- Molecular Imaging -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Therapeutics Industry Perspective -- Diagnostics Industry Perspective -- NCI Perspective -- Clinical Investigator Perspective -- Biomarker Development and Regulatory Oversight -- FDA Critical Path Initiative -- Oversight of Diagnostic Tests -- Designing Clinical Studies of Biomarkers -- Assessment and Adoption of Biomarker-Based Technologies -- Federal Programs for Technology Assessment -- Insurance Coverage Decisions and Practice Guidelines -- CMS Coverage of Biomarkers -- Economic Impact of Biomarkers -- Cost-Effectiveness Analysis -- The Value of Information and Research -- Technology Assessment in the Private Sector -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants -- Last Page.
|
588 |
0 |
|
|a Print version record.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Tumor markers
|v Congresses.
|
650 |
1 |
2 |
|a Neoplasms
|x prevention & control
|
650 |
2 |
2 |
|a Mass Screening
|x methods
|
650 |
2 |
2 |
|a Biomarkers, Tumor
|x analysis
|
650 |
|
6 |
|a Marqueurs tumoraux
|v Congrès.
|
650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
650 |
|
7 |
|a Tumor markers.
|2 fast
|0 (OCoLC)fst01158752
|
655 |
|
2 |
|a Congress
|
655 |
|
7 |
|a Conference papers and proceedings.
|2 fast
|0 (OCoLC)fst01423772
|
655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
655 |
|
7 |
|a Actes de congrès.
|2 rvmgf
|
700 |
1 |
|
|a Nass, Sharyl J.
|
710 |
2 |
|
|a National Cancer Policy Forum (U.S.)
|
710 |
1 |
|
|a United States.
|b Department of Health and Human Services.
|
776 |
0 |
8 |
|i Print version:
|a Patlak, Margie.
|t Developing biomarker-based tools for cancer screening, diagnosis, and treatment.
|d Washington, D.C. : National Academies Press, ©2006
|z 0309101344
|z 9780309101
|w (DLC) 2006025684
|w (OCoLC)70874173
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=178871
|z Texto completo
|
938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH36616883
|
938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH36567697
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3378153
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 178871
|
938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n 70492
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 2514804
|
994 |
|
|
|a 92
|b IZTAP
|